Tocris Bioscience™ aTAG 4531

Description

Degrader of MTH1 fusion proteins for use within the aTAG system

aTAG 4531 is a degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide (Cat. No. 0652). Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.34 nM; Dmax = 93.14%). Cell-permeable. Suitable for in vitro and in vivo applications.

Mouse DMPK properties are provided in the supplementary file (see below).

MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in. See protocol for more information.

Custom knock-in cell lines for the dTAG and aTAG platforms are available from our sister brand R&D Systems . Email TPD@bio-techne.com to enquire.

Specifications

• Chemical Name or Material: N-Cyclopropyl-6-(4-((4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)-1 H-1,2,3-triazol-1-yl)butyl)carbamoyl)-3-fluorophenyl)-7-fluoro-4-(phenylamino)quinoline-3-carboxamide
• CAS: 2412985-00-1
• Quantity: 5 mg
• Target: TAG Degradation Platforms
• Molecular Formula: C₄₆H₃₉F₂N₉O₇
• Purity: 98%